Group items tagged

The overall goals of the Bioinformatics Center are to provide a database and associated tools for storage and integration of clinical physiological and metabolic data along with multiple types of chemical analysis data derived through metabolomics, proteomics, genomics, transcriptomics, or similar technologies. 

This Funding Opportunity Announcement (FOA) invites research projects to improve understanding of the causes of high priority diseases in the United States and reducing/eliminating health disparities. Research is encouraged in the following high priority diseases within the scientific mission areas of the NIDDK: diabetes; obesity; nutrition-related disorders; hepatitis C; gallbladder disease; H. Pylori infection; sickle cell disease, specifically, studies in complications of sickle cell disease within the NIDDK mission areas; kidney diseases; urologic diseases; hematologic diseases, including studies in abnormal hemoglobin synthesis; metabolic diseases; gastrointestinal, hepatic, and renal complications from infection with HIV. Clinical trials are not permitted in response to this FOA.

The primary aim of this Ideas Lab is to foster the development of a theoretical framework that encompasses the "metabolism first" and "RNA first" theories for the origin of life by stimulating creative thinking and new research on the earliest events leading to life on early Earth. Understanding plausible pathways for the origin of life will contribute directly to our understanding of the indispensable properties of life on Earth and inform our search for life on other worlds.

With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-​effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC&'s current research priorities: Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. Developing testing protocols to detect designer substances used for doping purposes. Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. Developing analytical methods to detect performance enhancing drugs not currently detectable. Longitudinal urinary excretion patterns, metabolism and dose-concentration. Critical reviews to support interpretation of laboratory data. Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing. APPLY FOR A GRANT Sign up for our newsletter

The purpose of this funding opportunity is to establish a program of research to advance the understanding, prevention and treatment of pediatric multiple organ dysfunction syndrome (MODS). Given the prevalence and associated morbidity and mortality of MODS in children, the current lack of understanding underscores the need for more exploratory research. Possible topics of study include, but are not limited to, the epidemiology, pathophysiology, monitoring, and treatment of MODS. Studies that assess specific etiologies associated with MODS including, but not limited to, sepsis, trauma, acute respiratory distress syndrome, inborn errors of metabolism, burns, cancer, transplantation and congenital heart disease are encouraged. Applications may include any appropriate study design ranging from basic science animal models through small prospective randomized controlled trials. The intent of this R21 funding initiative is to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of research projects addressing these topics. These studies may incur considerable research risk in efforts to make important breakthroughs in the understanding, prevention and treatment of MODS in children. Projects of limited cost or scope that use widely accepted approaches and methods within well-established fields are better suited for the R03 small grant activity code. It is hoped that the results of this exploratory research will translate into improved clinical outcomes for children with, and at risk for MODS.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research on the role of the nervous system in metabolism, homeostasis, remodeling and/or regeneration of the postnatal dental and craniofacial skeletal system (DCS) in health and disease. The objectives are to enhance basic science knowledge about interactions between the peripheral and central nervous systems (PNS/CNS) and the DCS, and facilitate development of strategies to optimize normal function, reduce the impact of disease, and develop capacity to repair and regenerate injured teeth and craniofacial bones. 

Roche is pleased to announce that we are accepting applications for the 2013 TCRC Young Investigators Award.  The awards are intended to provide support for the earlier stages of scientific research career development, so they are to be awarded to the employing institutions of promising emerging researchers.  Proposals will be evaluated based on scientific merit and innovation of the projects proposed to be conducted using the awards.   Four awards will be presented on Oct 1, 2013 during the scientific symposium inaugurating Roche's Translational and Clinical Research Center in New York City.   Researchers performing investigations (clinical, in vitro/in vivo or informatics) focused on disease understanding of the following disease areas are encouraged to apply: Cardiovascular & Metabolism - Diabetes and related complications   Neuroscience - Spinal Muscular Atrophy Virology - Influenza Oncology - Treatment and diagnosis of Acute Myeloid Leukemia (AML).

This Funding Opportunity Announcement (FOA) issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites submission of investigator-initiated program project applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, endocrine and metabolic diseases, digestive diseases and nutrition, and kidney, urologic and hematologic diseases, as well as new approaches to prevent, treat and cure these diseases, including clinical research. A description of NIDDK scientific program areas can be found at http://www2.niddk.nih.gov/Funding/default.htm.

This Funding Opportunity Announcement (FOA) encourages grant applications from institutions or organizations that propose multidisciplinary, investigator-initiated basic and translational research in developmental pharmacology and toxicology. Particular emphasis should be placed on the role of ontogeny on drug metabolizing enzymes, transporters, receptors and signaling pathways across developmental periods from fetal life to adolescence affecting drug action and toxicity.

This Funding Opportunity Announcement (FOA) encourages grant applications from institutions or organizations that propose multidisciplinary, investigator-initiated basic and translational research in developmental pharmacology and toxicology. Particular emphasis should be placed on the role of ontogeny on drug metabolizing enzymes, transporters, receptors and signaling pathways across developmental periods from fetal life to adolescence affecting drug action and toxicity.

This Funding Opportunity Announcement (FOA) encourages grant applications for research related to developmental pharmacology and toxicology. A major goal is to encourage multidisciplinary, investigator-initiated basic and translational research in developmental pharmacology and toxicology with particular emphasis on the role of ontogeny on drug metabolizing enzymes, transporters, receptors and signaling pathways across developmental periods from fetal life to adolescence.

The Biotechnology, Biochemical, and Biomass Engineering (BBBE) program supports fundamental engineering research that advances the understanding of cellular and biomolecular processes (in vivo, in vitro, and/or ex vivo) and eventually leads to the development of enabling technology and/or applications in support of the biopharmaceutical, biotechnology, and bioenergy industries, or with applications in health or the environment.  Quantitative assessments of bioprocesses are considered vital to successful research projects in the BBBE program.  Fundamental to many research projects in this area is the understanding of how biomolecules and cells interact in their environment, and how those molecular level interactions lead to changes in structure, function, phenotype, and/or behavior.  The program encourages proposals that address emerging research areas and technologies that effectively integrate knowledge and practices from different disciplines, and effectively incorporate ongoing research into educational activities. Research projects of particular interest in BBBE include, but are not limited to: Metabolic engineering and synthetic biology Quantitative systems biotechnology Tissue engineering and stem cell culture technologies Protein engineering/protein design Development of novel "omics" tools for biotechnology applications

Validated biomarkers that detect risk, stage the disease, and predict its rate of progression in the at-risk setting for T1D are required to conduct more efficient clinical trials. These biomarkers may include markers of beta cell stress, dysfunction, and damage, functional beta cell mass,  autoimmune/inflammatory biomarkers, and/or biomarkers of impaired glucose and metabolic control. While progress has been made in identifying predictive markers for risk of T1D, there may be alternative molecular biomarkers (metabolites, proteomics, gene expression patterns, additional autoantibodies, etc.) that may prove to be expressed earlier, be more highly predictive, and/or more cost effective for detecting risk. Biomarkers that detect activation of innate immunity  or of T cells specific for beta cells, islet inflammation or beta cell stress, dysfunction or damage may be demonstrated to serve this role.

PoLS encourages research that emphasizes the physical principles of organization and function of living systems, including the exploration of artificial life forms. While the problems under study must be important to advancing our understanding of the living world in a quantitative way, particular emphasis will be placed on those projects in which lessons learned from the biological application also expand the intellectual range of physics. Awards will cover a broad spectrum of physics approaches in biology, ranging from the physical principles and mechanisms at the single cell level such as cellular organization (e.g. cytoskeleton), energy metabolism, gene regulation and intracellular and intercellular communication, to collective behavior and evolution of complexity in life forms and living populations of organisms. This systems approach in physics has been very successful in understanding inanimate systems, and has the potential to bring deep understanding of the world of animated, replicating systems, through testable phenomenological theories. The program funds individual investigators, although collaborative proposals between physicists and biological researchers are welcome. Proposals with potential societal impact such as renewable energy and human health are good examples of strong broader impact and are of interest to the program.

The U.S. Environmental Protection Agency (EPA), as part of its Science to Achieve Results (STAR) program, is seeking applications for research centers to investigate toxic effects of chemical substances in three-dimensional (3D) in vitro models, hereafter referred to as 'organotypic culture models' (OCMs). OCMs are tissue culture models that mimic in vivo tissue architecture through interactions of heterotypic cell types (e.g., epithelium-stroma) and extracellular matrices (ECM). They can be established from isolated cells or from tissue fragments harvested in vivo, and will bridge the gap between conventional monolayer cell cultures and whole-animal systems. EPA is interested in the potential application of OCMs that mimic complex cell arrangements and physiologies, scalable from mid to higher throughput screening (HTS), and high-content screening (HCS) approaches. This solicitation seeks the formation of research centers that will guide the development and evaluation of OCMs that will accelerate translational research in predictive toxicology. Three dimensional tissue models may, for example, utilize animal cells combined with mechanical scaffolds or microfluidics devices. Under this solicitation, the successful applicant will lead a Center to craft OCMs that can recapitulate critical features of in vivo cellular organization and communication, cell-matrix interplay, morphogenetic processes and differentiation, physiology and chemical metabolism. 

Diseases Network (UDN) building upon the NIH Intramural Research Programs Undiagnosed Diseases Program (NIH-UDP). Responsive applications will propose to investigate the underlying genetics, biochemistry and/or pathophysiology of newly diagnosed diseases in association with the respective gene variant(s) identified through the UDN. In recent years, gene function studies combined with genetic and genomic analyses and metabolic studies have greatly improved diagnoses of these very rare diseases and advanced scientific knowledge of the underlying pathogenesis. This initiative is funded through the NIH Common Fund, which supports cross-cutting programs that are expected to have exceptionally high impact.

his Funding Opportunity Announcement (FOA) invites applications for Diabetes Research Centers, formerly named Diabetes Endocrinology Research Centers (DERCs) and Diabetes Research and Training Centers (DRTCs).Diabetes Research Centers are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases.

The PCC has supported world-class research since 2009, spending more than $8.0 M to support novel science. Research and grant-making are the foundation of the PCC and are the focus of everyday business activity. PCC-supported research contributes to a movement in addressing doping's root causes and ultimately decreasing the use of performance-enhancing drugs by all participants in all sports at all levels of play. With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: - Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. - Developing testing protocols to detect designer substances used for doping purposes. - Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. - Developing analytical methods to detect performance enhancing drugs not currently detectable. - Longitudinal urinary excretion patterns, metabolism and dose-concentration. - Critical reviews to support interpretation of laboratory data. - Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing.

The Office of Biological and Environmental Research (BER) of the Office of Science (SC), U.S. Department of Energy (DOE), hereby announces its interest in receiving applications for research that supports the Genomic Science research program (http://genomicscience.energy.gov). In this FOA, applications are requested for: i) Research to advance the development of promising new model organisms relevant to biofuels production , ii) development of novel microbial functional capabilities and biosynthetic pathways relevant to the production of advanced biofuels and the development of strategies to overcome associated metabolic challenges resulting from pathway modification, and iii) development of novel analytical technologies or high-throughput screening approaches relating to research in bullets i and ii.

With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: - Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. - Developing testing protocols to detect designer substances used for doping purposes. - Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. - Developing analytical methods to detect performance enhancing drugs not currently detectable. - Longitudinal urinary excretion patterns, metabolism and dose-concentration. - Critical reviews to support interpretation of laboratory data. - Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing.